Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study

Table 1 Clinical parameters of patients with PsA at baseline and 12 weeks following treatment

	Anakinra n = 10			Etanercept n = 15
	Week 0	Week 12	P-value	Week 0	Week 12	P-value
TJC28	9.5 (3 to 19)	7 (1 to 13)	0.033	11 (1 to 25)	2 (0 to 28)	0.004
TJC68	24.5 (9 to 52)	13.5 (3 to 35)	0.015	15 (3 to 57)	3 (0 to 38)	0.002
SJC28	8 (1 to 18)	5 (0 to 8)	0.032	4 (1 to 21)	1 (0 to 8)	0.005
SJC68	20.5 (6 to 27)	8 (0 to 23)	0.028	9 (3 to 43)	2 (0 to 16)	0.007
ESR	18.5 (3 to 79)	7.5 (2 to 46)	0.059	14 (4 to 91)	5 (1 to 26)	0.001
CRP	17 (4 to 70)	7.5 (0 to 29)	0.044	7 (0 to 42)	0 (0 to 18)	0.092
d VAS	66 (27 to 85)	47 (12 to 70)	0.051	44.5 (5 to 93)	15 (2 to 56)	0.002
p VAS	65.5 (21 to 91)	46.5 (20 to 75)	0.169	50 (22 to 93)	12 (2 to 66)	0.001
HAQ	1.25 (0.75 to 2.38)	1.13 (0.25 to 1.88)	0.057	1.13 (0 to 2.5)	0.25 (0 to 2.25)	0.01
DAS28	5.03 (3.77 to 7.16)	4.17 (2.35 to 5.98)	0.022	5.26 (3.08 to 6.95)	2.01 (0.14 to 5.35)	0.001

Median (range). d VAS, disease visual analogue scale; p VAS, pain visual analogue scale.

ISSN: 1478-6362